30 August, 2016
By Mathini Ilancheran, Senior Lead Analyst, Clinical R&D, Beroe Inc.
The core addressable early phase market is USD 11.9 billion growing with a CAGR of 2 – 3 percent. Early phase trials are outsourced at greater than 60 percent by pharma, as the trials are small in number and a captive unit requires a large amount of capital. The supply market for early phase is comprised by CROs, research centers, and academic institutes. The market size that is comprised by the CROs is estimated to be around USD 8 billion, which is about 67 percent of the early phase market. Academic institution and research institutes comprise the remaining market at USD 3.9 billion
COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)